Premium
Prostate‐specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells
Author(s) -
Lapidus Rena G.,
Tiffany Carol W.,
Isaacs John T.,
Slusher Barbara S.
Publication year - 2000
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/1097-0045(20001201)45:4<350::aid-pros10>3.0.co;2-u
Subject(s) - glutamate carboxypeptidase ii , prostate cancer , prostate , hyperplasia , cancer research , enzyme , pca3 , medicine , cancer , chemistry , biochemistry
BACKGROUND Prostate‐specific membrane antigen (PSMA) is a glutamate carboxypeptidase that cleaves terminal carboxy glutamates from both the neuronal dipeptide N‐acetylaspartylglutamate (NAAG) and gamma‐linked folate polyglutamate. The prostate enzyme has activity in both the membrane and cytosolic fractions termed PSMA and PSMA′, respectively. METHODS Using a NAAG hydrolytic radioenzymatic assay, we quantitated the enzymatic activity of PSMA and PSMA′ in normal, benign prostatic hyperplasia (BPH), and prostate cancer (PC) tissues from radical prostatectomies. PSMA enzyme activity was evaluated in each tissue type and expressed per milligram protein and epithelial cell content. RESULTS PSMA and PSMA′ enzyme activities were significantly elevated in prostate cancer when compared to normal prostate tissue and BPH. Ratios of PSMA to PSMA′ were also decreased in BPH as compared to cancerous and normal tissue. CONCLUSIONS Prostate carcinogenesis is associated with an elevation in PSMA and PSMA′ enzyme activity. In contrast, no such enhancement in PSMA activity is observed with benign neoplastic changes in BPH. Thus, the enhancement observed in prostate cancer is not simply related to a generalized prostatic hyperplasia, but is specific to its malignancy. Prostate 45:350–354, 2000. © 2000 Wiley‐Liss, Inc.